ArticleTrends in analytical chemistry : TRAC2024
Nanoplasmonics biosensors: At the frontiers of biomedical diagnostics.
Article in Trends in analytical chemistry : TRAC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrated microfluidic biosensors: shaping the future of quantitative life sciences and on-chip molecular diagnostics.Lab on a chip · 2026Review
- Machine Learning-Enabled Intelligent Analysis of Surface-Enhanced Raman Scattering: Methods, Applications, and Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Overcoming immunotherapy resistance in non-small cell lung cancer: a narrative review of related factors.Immunotherapy · 2025Review
- Rapid and On-Site Approaches for Determination of Polycyclic Aromatic Hydrocarbons in Water and Air by Surface-Enhanced Raman Spectroscopy.ACS omega · 2025Article
- Tunable and scalable production of nanostar particle platforms for diverse applications using an AI-integrated automated synthesis system.Journal of materials science · 2025Article
- Advancements in SERS: Revolutionizing Biomedical Analysis and Applications.Nanotheranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This article presents an overview of various nanoplasmonics biosensors and their diverse applications, focusing on recent developments in our laboratory. We describe the versatility and effectiveness of different plasmonics-active platforms, ranging from solid substrates to adaptable nanoparticles like gold nanostars and nanorattles. The "Inverse Molecular Sentinel" (iMS) biosensing technology uses surface-enhanced Raman scattering (SERS) to detect nucleotide biomarkers associated with diseases ranging from acute infections to several types of cancer. We have also developed SERS-based nanochip systems capable of detecting DNA targets related to infectious disease biomarkers such as HIV, malaria, and dengue, promising advancements in global health diagnostics. Further, nanorattle-based biosensors are designed as "lab-in-a-stick" devices for rapid head and neck cancer diagnosis. Other technologies include plasmonics-enhanced lateral flow immunoassay systems, smartphone-based biosensing, and implantable biosensors or "smart tattoo" systems. These nanoplasmonics biosensors open new frontiers to rapid, simple, and effective detection systems for biomedical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.